Clinical Scorecard: The Flu Vaccine Face-Off Ends in a Draw
At a Glance
| Category | Detail |
|---|---|
| Condition | Influenza in adults aged 65 years or older |
| Key Mechanisms | Comparison of adjuvanted vs high-dose influenza vaccines |
| Target Population | Adults aged 65 years or older |
| Care Setting | Routine clinical care |
Key Highlights
- Adjuvanted and high-dose vaccines showed similar effectiveness against laboratory-confirmed influenza.
- Study involved 429,595 patients from Kaiser Permanente Northern California.
- No statistically significant difference in effectiveness between vaccine formulations.
- Influenza A accounted for the majority of cases in both groups.
- Findings support continued use of either vaccine formulation for older adults.
Guideline-Based Recommendations
Diagnosis
- Polymerase chain reaction testing for confirmed influenza.
Management
- Both adjuvanted and high-dose vaccines are recommended for adults aged 65 years or older.
Monitoring & Follow-up
- Monitor for polymerase chain reaction-confirmed influenza and associated hospitalizations.
Risks
- Potential underrepresentation of milder influenza cases due to testing propensity.
Patient & Prescribing Data
Adults aged 65 years or older
Both vaccine formulations are effective; choice may depend on patient preference.
Clinical Best Practices
- Continue to offer both adjuvanted and high-dose vaccines to older adults.
- Consider local influenza circulation and geographic variation when administering vaccines.
Related Resources & Content
This content is an AI-generated, fully rewritten summary based on a published scholarly article. It does not reproduce the original text and is not a substitute for the original publication. Readers are encouraged to consult the source for full context, data, and methodology.
